Publications by authors named "Anneleen Vanhellemont"
Introduction: Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods for quantifying patients' preferences.
Methods: A survey incorporating DCE and SW was disseminated among European MM patients. The survey included attributes and levels informed by a previous qualitative study with 24 MM patients.
Purpose: Multiple myeloma (MM) patients with triple- and penta-refractory disease have a poor survival and limited treatment options. Selinexor, in combination with bortezomib and dexamethasone, demonstrated clinical activity in the STOMP study as well as in the BOSTON study in previously treated patients with disease refractory to a proteasome inhibitor (PI).
Patients And Methods: Here, we report a real-world case series of 7 heavily pretreated MM patients who had been extensively pretreated with bortezomib and had disease refractory to PIs, including carfilzomib; who were administered a starting dose of 100 mg of selinexor, 20-40 mg dexamethasone and 1.
Article Synopsis
- The study investigated what multiple myeloma (MM) patients value most in their treatment options, acknowledging uncertainties about long-term side effects and treatment effectiveness.
- It involved a literature review, discussions with 24 patients from Belgium, Finland, Romania, and Spain, and analyzed their concerns about treatment expectations, side effects, and their impacts on daily life.
- Key patient concerns included life-threatening side effects leading to organ damage, debilitating symptoms affecting mobility and independence, and fears of temporary treatment benefits overshadowed by severe chronic issues.